Neri B, Cecchettin M, Pacini P, Bartalucci S, Gemelli M T, Giorgi F
Istituto di Clinica Medica IV, Day-Hospital Oncologico, Università degli Studi di Firenze, Italy.
Cancer Invest. 1989;7(6):551-5. doi: 10.3109/07357908909017529.
Circulating osteocalcin (BGP), the major noncollagenous bone protein, is elevated in patients with certain metabolic bone disease while its behavior in cancer patients, particularly those with bone metastases, is unclear. We measured circulating BGP in 37 healthy females, in 13 female patients with benign breast disease, and in a group of 51 cancer patients (breast, lung, prostate, and bladder) with and without bone metastases, before and after 4'-epidoxorubicin (4'-Epidx) therapy (4'-Epidx 120 mg/m2 every 3 weeks). Under basal conditions, mean BGP levels of all of these subjects fell within the normal range of 2.0-5.0 ng/ml (mean +/- SD, 4.8 +/- 1.0 ng/ml). In cancer patients without bone metastases BGP levels measured before and after 4'-Epidx therapy were not significantly different (4.4 versus 4.6 ng/ml). Only in breast cancer patients with multiple bone metastases was circulating BGP higher after the onset of antiblastic treatment and through the entire course of therapy, accompanied by bone pain remission and regression of bone lesions (BGP = 6.7 +/- 1.3 ng/ml). Thus an increase in BGP concentration can be considered as a biological marker of recovered osteoblast activity during therapeutically induced stabilization or regression of skeletal metastatic lesions.
循环骨钙素（骨γ-羧基谷氨酸蛋白）是主要的非胶原蛋白，在某些代谢性骨病患者中水平升高，而其在癌症患者，尤其是有骨转移的患者中的表现尚不清楚。我们测量了37名健康女性、13名患良性乳腺疾病的女性患者以及51名有或无骨转移的癌症患者（乳腺癌、肺癌、前列腺癌和膀胱癌）在接受4'-表阿霉素（4'-Epidx）治疗（每3周120mg/m² 4'-Epidx）前后的循环骨钙素水平。在基础条件下，所有这些受试者的平均骨钙素水平均在2.0 - 5.0ng/ml的正常范围内（均值±标准差，4.8±1.0ng/ml）。在无骨转移的癌症患者中，4'-Epidx治疗前后测量的骨钙素水平无显著差异（4.4对4.6ng/ml）。仅在有多发性骨转移的乳腺癌患者中，抗成骨细胞治疗开始后及整个治疗过程中循环骨钙素水平升高，同时伴有骨痛缓解和骨病变消退（骨钙素 = 6.7±1.3ng/ml）。因此，骨钙素浓度升高可被视为在治疗诱导的骨骼转移性病变稳定或消退过程中，成骨细胞活性恢复的生物学标志物。
